| Comparison 1. Fluticasone versus placebo | ||||||
|---|---|---|---|---|---|---|
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Placebo | Fluticasone | |||||
| Time to first exacerbation Follow-up: 6 months | 460 per 10001 | 483 per 1000 (342 to 645)1 | HR 1.07 (0.68 to 1.6838)2 | 171 (Balfour-Lynn 2006) | ⊕⊕⊝⊝ low1 | |
| Growth (change in height) SDS (standard deviation) score Follow-up: 12 months | The mean growth (change in height) in the placebo groups was −0.01 SDS | The mean growth (change in height) in the fluticasone groups was 0.37 SDS lower (0.77 lower to 0.03 higher) | 30 (De Boeck 2007) | ⊕⊕⊕⊝ moderate3 | ||
| Growth (change in height) in paediatric participants cm Follow-up: 8 months | The mean growth (change in height) in paediatric participants in the placebo groups was 3.5 cm | The mean growth (change in height) in paediatric participants in the fluticasone groups was 0.6 cm higher (0.46 lower to 1.66 higher) | 80 (Balfour-Lynn 2006) | ⊕⊕⊕⊝ moderate3 | ||
The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
Abbreviations: CI: confidence interval; HR: hazard ratio; MD: mean difference; SDS: standard deviation score
The quality of the evidence was downgraded by 2 as 95%CI crossed the null effect line, and it is very wide.
Calculated by the NGA technical team from percentage of participants in group with at least 1 exacerbation.
The quality of the evidence was downgraded by 1 because 95%CI crossed 1 default MID.
From: 9, Pulmonary monitoring, assessment and management
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.